Moors & Cabot’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-4
Closed -$3K – 921
2021
Q4
$3K Buy
+4
New +$1.55K ﹤0.01% 881

Other funds holding CRL

Moors & Cabot's CRL Position: Q3 2026 in Review

Moors & Cabot reduced its Charles River Laboratories (CRL) stake by 1.7% in Q3 2026, selling an estimated $7.91K and leaving 1,701 shares worth $502K. The position accounts for 0.02% of the portfolio, ranked #569.

Moors & Cabot first reported a position in CRL in Q3 2021 and has held it in 21 quarters since. The position peaked at $743K in Q3 2021. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Moors & Cabot held 1,701 shares of Charles River Laboratories worth $502K as of Q3 2026.
  • Moors & Cabot sold 30 Charles River Laboratories shares in Q3 2026, an estimated $7.91K.
  • Charles River Laboratories made up 0.02% of Moors & Cabot's portfolio in Q3 2026, its #569 holding.
  • Moors & Cabot first reported a position in Charles River Laboratories in Q3 2021 and has held it in 21 quarters since.
  • Moors & Cabot's Charles River Laboratories position peaked at $743K in Q3 2021.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Moors & Cabot's 13F filing for Q3 2026, filed 6 Nov 2026.